Definium Therapeutics says synthetic LSD trial shows positive anxiety results; shares jump as stock is up 190% in 2026
Definium Therapeutics reported positive results for synthetic LSD in reducing anxiety symptoms, triggering another sharp share move after a 190% year-to-date run. The update reinforces risk appetite in early-stage biotech and highlights continued investor willingness to re-rate clinical-stage names on trial readouts. Near-term impact should be concentrated in single-name biotech volatility rather than broader macro or crypto markets.
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Definium Therapeutics said its synthetic LSD delivered positive results in easing anxiety symptoms, sending the stock sharply higher again after the announcement. The company’s shares are up 190% in 2026. The clinical trial success further lifted investor confidence.